369 research outputs found
sj-docx-1-jcn-10.1177_08830738221118807 - Supplemental material for Thalamic Volume Loss Is Greater in Children Than in Adults Following Middle Cerebral Artery Territory Arterial Ischemic Stroke
No full textSupplemental material, sj-docx-1-jcn-10.1177_08830738221118807 for Thalamic Volume Loss Is Greater in Children Than in Adults Following Middle Cerebral Artery Territory Arterial Ischemic Stroke by Emily J. Mastej, Michelle H. Leppert, Sharon Poisson, Zak Ritchey, Megan Barry, Tatjana Rundek, David S. Liebeskind, David Mirsky, Timothy J. Bernard and Nicholas V. Stence in Journal of Child Neurology</p
sj-docx-1-tan-10.1177_17562864241239101 – Supplemental material for Serum neurofilament light chain correlations in patients with a first clinical demyelinating event in the REFLEX study: a post hoc analysis
No full textSupplemental material, sj-docx-1-tan-10.1177_17562864241239101 for Serum neurofilament light chain correlations in patients with a first clinical demyelinating event in the REFLEX study: a post hoc analysis by Jens Kuhle, David Leppert, Giancarlo Comi, Nicola de Stefano, Ludwig Kappos, Mark S. Freedman, Andrea Seitzinger and Sanjeev Roy in Therapeutic Advances in Neurological Disorders</p
Fluid biomarker and electrophysiological outcome measures for progressive MS trials
No full text Progressive multiple sclerosis (MS) is characterized by insidious clinical worsening that is difficult to accurately quantify and predict. Biofluid markers and electrophysiological measures are potential candidate outcome measures in clinical trials, allowing the quantification of nervous damage occurring in the disease. Neurofilaments are highly specific neuronal proteins. They may have come closest to such applications by their higher concentrations repeatedly demonstrated in cerebrospinal fluid (CSF) in all stages of MS, during relapses, their responsiveness to disease-modifying treatments in relapsing and progressive MS and their associations with measures of inflammatory and degenerative magnetic resonance imaging (MRI) outcomes. Digital single-molecule array (Simoa) technology improves accuracy of bioassays in the quantification of neurofilament light chain (NfL) in serum and plasma. NfL seems to mark a common final path of neuroaxonal injury independent of specific causal pathways. CSF and blood levels of NfL are highly correlated across various diseases including MS, suggesting that blood measurements may be useful in assessing response to treatment and predicting future disease activity. Other biomarkers like matrix metalloproteinases, chemokines, or neurotrophic factors have not been studied to a similar extent. Such measures, especially in blood, need further validation to enter the trial arena or clinical practice. The broadening armamentarium of highly sensitive assay technologies in the future may shed even more light on patient heterogeneity and mechanisms leading to disability in MS. Evoked potentials (EPs) are used in clinical practice to measure central conduction of central sensorimotor pathways. They correlate with and predict the severity of clinical involvement of their corresponding function. Their validation for use in multicenter studies is still lacking, with the exception of visual EPs. If further validated, EPs and fluid biomarkers would represent useful outcome measures for clinical trials, being related to specific mechanisms of the ongoing pathologic changes. </jats:p
Blood and CSF biomarkers for multiple sclerosis: emerging clinical applications
No full textNeurofilament light chain (NfL), glial fibrillary acidic protein (GFAP), chitinase-3-like protein 1 (CHI3L1), and other protein assays are being developed as diagnostic or prognostic biomarkers in multiple sclerosis. An increase in NfL concentrations reflects axonal damage resulting from the acute new inflammatory disease activity that occurs during a relapse. NfL concentrations can also reflect the occurrence of new MRI lesions. GFAP concentrations are increased in people with progressive forms of multiple sclerosis, and GFAP is an emerging biomarker of progression independent of relapses. CHI3L1 is an emerging biomarker associated with progression independent of relapse activity and several MRI lesion types, including paramagnetic rim lesions. Some biomarkers, particularly NfL, can help monitoring treatment response, and combinations of multivariate biomarkers provide additional accuracy in specific clinical scenarios. In multiple sclerosis, fluid-based biomarkers are quickly emerging as instruments for clinical monitoring of disease course and patients' response to treatment
MSO906844 Supplemental Material - Supplemental material for White matter lesion location correlates with disability in relapsing multiple sclerosis
No full textSupplemental material, MSO906844 Supplemental Material for White matter lesion location correlates with disability in relapsing multiple sclerosis by Laura Gaetano, Baldur Magnusson, Petya Kindalova, Davorka Tomic, Diego Silva, Anna Altermatt, Stefano Magon, Nicole Müller-Lenke, Ernst-Wilhelm Radue, David Leppert, Ludwig Kappos, Jens Wuerfel, Dieter A Häring and Till Sprenger in Multiple Sclerosis Journal—Experimental, Translational and Clinical</p
sj-docx-3-msj-10.1177_13524585211047977 – Supplemental material for Measurement of neurofilaments improves stratification of future disease activity in early multiple sclerosis
No full textSupplemental material, sj-docx-3-msj-10.1177_13524585211047977 for Measurement of neurofilaments improves stratification of future disease activity in early multiple sclerosis by Tomas Uher, Eva Kubala Havrdova, Pascal Benkert, Niels Bergsland, Jan Krasensky, Barbora Srpova, Michael Dwyer, Michaela Tyblova, Stephanie Meier, Manuela Vaneckova, Dana Horakova, Robert Zivadinov, David Leppert, Tomas Kalincik and Jens Kuhle in Multiple Sclerosis Journal</p
sj-tiff-1-msj-10.1177_13524585211047977 – Supplemental material for Measurement of neurofilaments improves stratification of future disease activity in early multiple sclerosis
No full textSupplemental material, sj-tiff-1-msj-10.1177_13524585211047977 for Measurement of neurofilaments improves stratification of future disease activity in early multiple sclerosis by Tomas Uher, Eva Kubala Havrdova, Pascal Benkert, Niels Bergsland, Jan Krasensky, Barbora Srpova, Michael Dwyer, Michaela Tyblova, Stephanie Meier, Manuela Vaneckova, Dana Horakova, Robert Zivadinov, David Leppert, Tomas Kalincik and Jens Kuhle in Multiple Sclerosis Journal</p
Pomegranate juice consumption reduces simulated ischemic stroke damage and increases brain antioxidant status in rats
No full textPomegranate phytochemicals / Navindra P. Seeram ... [et al.] -- Antioxidative properties of pomegranate : in vitro studies / Mira Rosenblat and Michael Aviram -- Bioavailability of pomegranate polyphenols / Francisco A. Tom?s-Barber?n, Navindra P. Seeram, and Juan Carlos Esp?n -- Protection against cardiovascular disease / Bianca Fuhrman and Michael Aviram -- Protection against stroke / Marva I. Sweeney-Nixon -- Anticancer potential of pomegranate / Shishir Shishodia ... [et al.] -- Molecular mechanisms of chemoprevention of cancer by pomegranate / Deeba Syed ... [et al.] -- Pomegranate and prostate cancer chemoprevention / John T. Leppert and Allan J. Pantuck -- Assessment of estrogenicity of pomegranate in an in vitro bioassay / Diane M. Harris, Emily Besselink, and Navindra P. Seeram -- Absence of significant estrogenic effects in the postmenopausal population / Michelle P. Warren ... [et al.] -- Antimicrobial activities of pomegranate / G.K. Jayaprakasha, P.S. Negi, B.S. Jena -- Commercialization of pomegranates : fresh fruit, beverages, and botanical extracts / Navindra P. Seeram, Yanjun Zhang, and David Heber -- Pomegranates: a botanical perspective / David W. Still -- Postharvest biology and technology of pomegranates / Adel A. Kader
sj-pdf-2-tan-10.1177_17562864221080528 – Supplemental material for Neuro-axonal injury in COVID-19: the role of systemic inflammation and SARS-CoV-2 specific immune response
No full textSupplemental material, sj-pdf-2-tan-10.1177_17562864221080528 for Neuro-axonal injury in COVID-19: the role of systemic inflammation and SARS-CoV-2 specific immune response by Cédric Hirzel, Denis Grandgirard, Bernard Surial, Manon F. Wider, David Leppert, Jens Kuhle, Laura N. Walti, Joerg C. Schefold, Thibaud Spinetti, Franziska Suter-Riniker, Ronald Dijkman and Stephen L. Leib in Therapeutic Advances in Neurological Disorders</p
sj-pdf-1-tan-10.1177_17562864221080528 – Supplemental material for Neuro-axonal injury in COVID-19: the role of systemic inflammation and SARS-CoV-2 specific immune response
No full textSupplemental material, sj-pdf-1-tan-10.1177_17562864221080528 for Neuro-axonal injury in COVID-19: the role of systemic inflammation and SARS-CoV-2 specific immune response by Cédric Hirzel, Denis Grandgirard, Bernard Surial, Manon F. Wider, David Leppert, Jens Kuhle, Laura N. Walti, Joerg C. Schefold, Thibaud Spinetti, Franziska Suter-Riniker, Ronald Dijkman and Stephen L. Leib in Therapeutic Advances in Neurological Disorders</p
- …
